Acasă › Cancer de sân triplu negativ › Tennessee › Nashville
Studii clinice pentru Cancer de sân triplu negativ în Nashville, TN
28 studii pentru Cancer de sân triplu negativ caută participanți în și în jurul orașului Nashville (în aproximativ 50 km). Deschideți un studiu pentru a vedea criteriile de eligibilitate și cum să contactați echipa de cercetare.
Text oficial al studiului (în engleză)
A Phase 1 Study of PLN-101095 in Adults With Advanced or Metastatic Solid Tumors
În curs de recrutareFaza 1
- Tennessee Oncology, Nashville
A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors
În curs de recrutareFaza 1
- Sarah Cannon Research Institute, Nashville
- Tennessee Oncology PLLC, Nashville
The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
În curs de recrutareFaza 1/2
- Sarah Cannon Research Institute, Nashville
A Study With NKT3964 for Adults With Advanced/Metastatic Solid Tumors
În curs de recrutareFaza 1
- Sarah Cannon Research Institute (SCRI), Nashville
Testing the Addition of Anti-Cancer Drug, ZEN003694 (ZEN-3694) and PD-1 Inhibitor (Pembrolizumab), to Standard Chemotherapy (Nab-Paclitaxel) Treatment in Patients With Advanced Triple-Negative Breast Cancer
În curs de recrutareFaza 1
- Vanderbilt Breast Center at One Hundred Oaks, Nashville
First-in-Human Study of ATX-295, an Oral Inhibitor of KIF18A, as Monotherapy and in Combination With Anticancer Therapy in Patients With Advanced or Metastatic Solid Tumors, Including Ovarian Cancer
În curs de recrutareFaza 1/2
- SCRI Oncology Partners, Nashville
Solid Tumor Analysis for HLA Loss of Heterozygosity (LOH) and Apheresis for CAR T- Cell Manufacturing
În curs de recrutareStudiu observațional
- Vanderbilt University Medical Center, Nashville
A Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Triple-Negative Breast Cancer (MK-2870-011/TroFuse-011)
În curs de recrutareFaza 3
- SCRI Oncology Partners ( Site 7004), Nashville
- Tennessee Oncology ( Site 0018), Nashville
Sacituzumab Tirumotecan (MK-2870) Plus Pembrolizumab Versus TPC in TNBC Who Did Not Achieve pCR (MK-2870-012)
În curs de recrutareFaza 3
- One Oncology - Tennessee Oncology ( Site 0098), Nashville
- SCRI Oncology Partners ( Site 7000), Nashville
- Tennessee Oncology ( Site 0111), Nashville
- și încă 1
A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)
În curs de recrutareFaza 3
- SCRI Oncology Partners ( Site 7005), Nashville
- Nashville General Hospital ( Site 0017), Nashville
- Vanderbilt-Ingram Cancer Center ( Site 0038), Nashville
Evaluate BL-B01D1 in Patients With Metastatic or Unresectable Non-Small Cell Lung Cancer (NSCLC) and Other Solid Tumors
În curs de recrutareFaza 1
- Sarah Cannon - Tennessee Oncology, Nashville
Phase 1 Study of a Self-amplifying RNA Vaccine (ITI-5000) in Stage 2-3 Triple Negative Breast Cancer
În curs de recrutareFaza 1
- Sarah Cannon Research Institute, Nashville
Evaluating Minimal Residual Disease (MRD) Through Longitudinal Circulating Tumor DNA (ctDNA) Profiling in Breast Malignancies
În curs de recrutareStudiu observațional
- Nashville General, Nashville
A Phase 1 Study of NRM-823 in Participants With Locally Advanced or Metastatic Refractory Solid Tumors
În curs de recrutareFaza 1
- Normunity Investigational Site, Nashville
A Study of BMS-986340 as Monotherapy and as Combination Therapy in Participants With Advanced Solid Tumors
În curs de recrutareFaza 1/2
- Vanderbilt University Medical Center, Nashville
SMP-3124LP in Adults With Advanced Solid Tumors
În curs de recrutareFaza 1/2
- SCRI Oncology Partners, Nashville
- Vanderbilt-Ingram Cancer Center, Nashville
Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)
În curs de recrutareFaza 1/2
- Sarah Cannon Research Institute at Tennessee Oncology, Nashville
- Tennessee Oncology, Nashville
A Phase 1 of CTX-8371 in Patients With Advanced Malignancies
În curs de recrutareFaza 1
- Tennessee Oncology, Nashville
A Study of Emiltatug Ledadotin (Emi-Le) in Participants With Solid Tumors
În curs de recrutareFaza 1/2
- Sarah Cannon Research Institute (SCRI), Nashville
Circulating Tumor DNA to Guide Changes in Standard of Care Chemotherapy
În curs de recrutareFaza 2
- Vanderbilt University/Ingram Cancer Center, Nashville
A Study of LY4175408 in Participants With Advanced Cancer
În curs de recrutareFaza 1
- Sarah Cannon Research Institute, Nashville
Study of XB010 in Subjects With Solid Tumors
În curs de recrutareFaza 1
- SCRI Oncology Partners, Nashville
A Study of IDE034 in Adult Participants With Locally Advanced/Metastatic Solid Tumors Types
În curs de recrutareFaza 1
- SCRI Oncology Partners, Nashville
Pilot Study of Bone Mineral Density Changes During Anti-PD-1 Immunotherapy
În curs de recrutare
- Vanderbilt-Ingram Cancer Center, Nashville
Atezolizumab + Sacituzumab Govitecan to Prevent Recurrence in TNBC (ASPRIA)
În curs de recrutareFaza 2
- Vanderbilt-Ingram Cancer Center, Nashville
A Study of Sacituzumab Govitecan Given at an Alternative Dose and Schedule in Participants With Advanced Triple-Negative Breast Cancer
În curs de recrutareFaza 1/2
- SCRI Oncology Partners, Nashville
- Tennessee Oncology, PLLC, Nashville
Neoadjuvant Darolutamide Alone or in Combination With Standard Therapy for Stage II-IIIA, AR+, TNBC
În curs de recrutareFaza 2
- Vanderbilt University/Ingram Cancer Center, Nashville
A Phase 2 Study of PCS6422 With Capecitabine in Patients With Advanced or Metastatic Breast Cancer
În curs de recrutareFaza 2
- SCRI Oncology Partners, Nashville
Studii pentru Cancer de sân triplu negativ în alte orașe
- Houston, TX42 studii
- New York City, NY31 studii
- Los Angeles, CA27 studii
- Boston, MA26 studii
- San Antonio, TX23 studii
- St. Louis, MO21 studii
- Arlington, VA20 studii
- Atlanta, GA20 studii
- Dallas, TX18 studii
- Chicago, IL16 studii
- Columbus, OH16 studii
- Grand Rapids, MI15 studii
Alte studii în Nashville
- Cancer pulmonar cu celule non-pătrate97 studii
- Cancer de sân81 studii
- Cancer metastatic70 studii
- Cancer colorectal69 studii
- Cancer (toate tipurile)65 studii
- Cancer ovarian49 studii
- Cancer de prostată43 studii
- Cancer pulmonar40 studii
- Carcinom cu celule scuamoase de cap și gât39 studii
- Cancer pancreatic39 studii
- Cancer endometrial38 studii
- Melanom33 studii
Sursă: ClinicalTrials.gov, date preluate la 6 oct. 2026. Fiecare studiu are propriile criterii de eligibilitate; echipa de cercetare decide cine poate participa.